Syntaxin lands $33M for promising platform

The venture capital arm of GlaxoSmithKline, SR One, has co-led a $33 million venture round for the UK's Syntaxin--a developer focused on cell secretion. The Series B was also co-led by Life Science Partners. Syntaxin's technology is being used to develop proteins that can prevent a cell from secreting hormones or the signaling molecules the play a key role in disease.

"Syntaxin's discovery platform provides a unique approach to the development of a new class of biopharmaceutical products with potential application across a broad range of indications," said Deborah Harland, general partner at SR One.

- see this release for more

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.